Efficacy of Cichorium intybus on Alanine Aminotransferase in Non- alcoholic Fatty Liver Disease: A Randomised Double-blind Clinical Trial with Placebo

Author: Maryam Nikkhajoei*, Rasool Choopani*, Mojgan Tansaz*, Fataneh Hashem-Dabaghian**, Ghazaleh Heydarirad*, Shamim Sahranavard*** and Medi Saberifiroozi****

Download PDF

Abstract

The present study assesses the efficacy of Cichorium intybus for the reduction of alanine aminotransferase (ALT) in Non-alcoholic fatty liver disease (NAFLD). This randomized double-blind clinical-trial with placebo study was carried out for 61 patients. One group received 500 mg/day of powder extract of root of C. intybus orally before breakfast for 8 weeks while the other group received starch. Their body mass index (BMI), triglyceride (TG), cholesterol (Chol), ALT, aspartate aminotransferase (AST), high density lipoprotein (HDL), low density lipoprotein (LDL), fasting blood sugar (FBS) and impaired glucose tolerance (IGT) were measured before and after the study. In C. intybus group, BMI, ALT, AST, IGT after treatments were reduced compare to baseline, P=0.03 for ALT and P=0.04 for AST, but there was no meaningful difference between the two groups (p≥0.5). C. intybus can reduce ALT in NAFLD but has no significant impact.

Keywords

Non-alcoholic fatty liver disease, Alanine aminotransferase, Cichorium intybus

Conclusion

The results of this study shows that C. intybus formula can reduce ALT as well as TG, Chol, AST, IGT and FBS in patients with NAFLD and/or NASH; nevertheless, further studies with more study population and longer evaluation time are necessary to better assess the efficacy and safety of C. intybus on NAFLD and/or NASH.

References

-

How to cite this article

Maryam Nikkhajoei, Rasool Choopani*, Mojgan Tansaz*, Fataneh Hashem-Dabaghian, Ghazaleh Heydarirad*, Shamim Sahranavard and Medi Saberifiroozi (2016). Efficacy of Cichorium intybus on Alanine Aminotransferase in Non- alcoholic Fatty Liver Disease: A Rando